The standard of care for osteomyelitis has not changed over the past half century: long-term intravenous antibiotics with multiple agents and doses administered daily and typically lasting a full 12 weeks, followed by oral medications for an additional several months to a year. Silver Bullet Therapeutics Inc. is developing a temporary, implantable silver-eluting implant to fight infection in tandem with IV antibiotics. The company's founders say it should shorten the duration of IV therapy by half.
2362 Qume Drive
Suite D
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.
Zidesamtinib would be the fifth ROS-1 targeting therapy on the market, but Nuvalent believes its safety and efficacy profile will make it the best in class.
Lilly-rejected candidate impresses in Phase IIb atopic dermatitis trial.
MariTide demonstrated solid 52-week weight loss in a Phase II update, but high rates of vomiting. Amgen is adjusting dosing in Phase III to seek a better tolerability profile.
Zidesamtinib would be the fifth ROS-1 targeting therapy on the market, but Nuvalent believes its safety and efficacy profile will make it the best in class.
Insights from Novotech on Evolving Trends Impacting Global Clinical Development
Lilly-rejected candidate impresses in Phase IIb atopic dermatitis trial.
